Comparing the current results to its competitors, Johnson And Johnson reported Revenue increase in the 2 quarter 2026 by 6.6 % year on year. The sales growth was above Johnson And Johnson's competitors' average revenue growth of 3.44 %, achieved in the same quarter.
Johnson and Johnson Net Income in the 2 quarter 2026 fell year on year by -0.05%, while most of its competitors have experienced a contraction in net income by -48.29 %.
Johnson And Johnson's Comment on Competition and Industry Peers
In all of their product lines, the Companys subsidiaries compete with companies
both locally and globally, throughout the world. Competition exists in all product
lines without regard to the number and size of the competing companies involved.
Competition in research, involving the development and the improvement of new
and existing products and processes, is particularly significant. The development
of new and innovative products is important to the Company’s success in
all areas of its business. This also includes protecting the Company’s portfolio
of intellectual property. The competitive environment requires substantial investments
in continuing research. In addition, the development and maintenance of customer
demand for the Company’s consumer products involves significant expenditures
for advertising and promotion.
With revenue growth of 6.6 % within Overall company, Johnson and Johnson achieved improvement in market share, within Overall company to approximately 20.74 %. << More on JNJ Market Share.
*Market share is calculated based on total revenue.
October 14, 2025
Johnson and Johnson s recent announcement of its intent to separate its Orthopaedics business signifies a strategic maneuver aimed at enhancing operational focus and driving stakeholder value. This article discusses the implications of this separation, evaluates the company s revenue performance relative to competitors, and examines net income trends in the broader MedTech landscape. In a significant shift aimed at refining its operational strategy, Johnson and Johnson (JandJ) recently declared its intent to separate its Orthopaedics business. Based in New Brunswick, N.J., JandJ is committed to maintaining its position as a leader in innovative medicine and MedTech areas that address high unmet needs. This ...
May 28, 2024
Johnson and Johnson Acquires Numab Subsidiary for $1.25 Billion Amid Revenue Declines but Improved Profit Margins NEW BRUNSWICK, N.J. In a strategic move to strengthen its portfolio in immunology and expand its presence in the dermatology market, Johnson and Johnson announced it has entered into a definitive agreement with Numab Therapeutics, a clinical-stage biotechnology company, to acquire the global rights to their innovative bispecific antibody, NM26. This investigational first-in-class therapy is poised to address diverse patient needs in atopic dermatitis and represents Johnson and Johnson s ongoing commitment to innovation and patient care.The acquisition will be an all-cash transaction valued at...
May 1, 2024
Johnson and Johnson (JandJ), a multinational pharmaceutical and personal care product company, has revealed a resolution strategy designed to address all current and future ovarian cancer claims arising from litigation related to cosmetic talc. This announcement was put forward by JandJ s subsidiary, LLT Management LLC, with the stated goal to accomplish a uniform and final resolution for all such claims directed at JandJ and its affiliates in the United States.Referred to as the Plan of Reorganization (the Plan), this intricate maneuver is the culmination of a consensual resolution strategy that was unveiled by the company in the October of the previous year. The specifics of the plan were not detailed in t...
Johnson and Johnson, a leading multinational pharmaceutical and medical devices company, recently held an Enterprise Business Review to discuss its strategic plans for long-term competitive growth. The event, which took place at the New York Stock Exchange, highlighted the company s overarching strategy, innovative product pipelines, and financial outlook. In today s rapidly evolving healthcare landscape, advancements in science and technology are expected to revolutionize human health. Johnson and Johnson recognizes this and aims to capitalize on the opportunities presented by personalized treatment and early intervention. By leveraging its extensive resources and expertise, the company aims to lea...
Third Harmonic Bio Inc's business model centers around developing and commercializing innovative therapeutic solutions through the utilization of bioinformatics and genomics.
AbbVie Inc operates primarily as a global biopharmaceutical company, focusing on the research, development, manufacturing, and commercialization of advanced therapies and medications in critical areas such as immunology, oncology, neuroscience, and virology. The company aims to improve patient outcomes and address unmet medical needs by leveraging its scientific expertise and capabilities while providing value to stakeholders in the healthcare industry.
Abbott Laboratories operates as a diversified healthcare company with a focus on developing and manufacturing a wide range of health-related products, including pharmaceuticals, medical devices, nutritional products, and diagnostic technologies. Their business model emphasizes innovation and quality, aiming to address the diverse needs of patients and healthcare providers across various sectors globally. By leveraging their expertise and extensive portfolio, Abbott strives to enhance patient outcomes and improve the overall quality of life.
Sources:
Johnson and Johnson’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Johnson and Johnson versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
